Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 49 results:
Συντάκτης Τίτλος [ Τύπος(Desc)] Έτος
Φίλτρα: Συντάκτης is Christodoulou, Christos  [Clear All Filters]
Journal Article
Kotoula, V., Bobos M., Alexopoulou Z., Papadimitriou C., Papadopoulou K., Charalambous E., et al. (2014).  Adjusting breast cancer patient prognosis with non-HER2-gene patterns on chromosome 17.. PLoS One. 9(8), e103707.
Kountourakis, P., Souglakos J., Gouvas N., Androulakis N., Athanasiadis A., Boukovinas I., et al. (2016).  Adjuvant chemotherapy for colon cancer: a consensus statement of the Hellenic and Cypriot Colorectal Cancer Study Group by the HeSMO.. Ann Gastroenterol. 29(1), 18-23.
Rallis, G., Koletsa T., Saridaki Z., Manousou K., Koliou G-A., Kostopoulos I., et al. (2019).  Association of Notch and Hedgehog Pathway Activation With Prognosis in Early-stage Colorectal Cancer.. Anticancer Res. 39(4), 2129-2138.
Psyrri, A., Kalogeras K. T., Wirtz R. M., Kouvatseas G., Karayannopoulou G., Goussia A., et al. (2017).  Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group.. J Transl Med. 15(1), 30.
Dervenis, C., Xynos E., Sotiropoulos G., Gouvas N., Boukovinas I., Agalianos C., et al. (2016).  Clinical practice guidelines for the management of metastatic colorectal cancer: a consensus statement of the Hellenic Society of Medical Oncologists (HeSMO).. Ann Gastroenterol. 29(4), 390-416.
Xynos, E., Gouvas N., Triantopoulou C., Tekkis P., Vini L., Tzardi M., et al. (2016).  Clinical practice guidelines for the surgical management of colon cancer: a consensus statement of the Hellenic and Cypriot Colorectal Cancer Study Group by the HeSMO.. Ann Gastroenterol. 29(1), 3-17.
Xynos, E., Tekkis P., Gouvas N., Vini L., Chrysou E., Tzardi M., et al. (2016).  Clinical practice guidelines for the surgical treatment of rectal cancer: a consensus statement of the Hellenic Society of Medical Oncologists (HeSMO).. Ann Gastroenterol. 29(2), 103-26.
Stavridi, F., Kalogeras K. T., Pliarchopoulou K., Wirtz R. M., Alexopoulou Z., Zagouri F., et al. (2016).  Comparison of the Ability of Different Clinical Treatment Scores to Estimate Prognosis in High-Risk Early Breast Cancer Patients: A Hellenic Cooperative Oncology Group Study.. PLoS One. 11(10), e0164013.
Mountzios, G., Kotoula V., Kolliou G-A., Papadopoulou K., Lazaridis G., Christodoulou C., et al. (2019).  Cyclin D1 differential activation and its prognostic impact in patients with advanced breast cancer treated with trastuzumab.. ESMO Open. 4(2), e000441.
Fountzilas, E., Kotoula V., Zagouri F., Giannoulatou E., Kouvatseas G., Pentheroudakis G., et al. (2016).  Disease evolution and heterogeneity in bilateral breast cancer.. Am J Cancer Res. 6(11), 2611-2630.
Fountzilas, G., Dafni U., Papadimitriou C., Timotheadou E., Gogas H., Eleftheraki A. G., et al. (2014).  Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial.. BMC Cancer. 14, 515.
Kotoula, V., Karavasilis V., Zagouri F., Kouvatseas G., Giannoulatou E., Gogas H., et al. (2016).  Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes.. Breast Cancer Res Treat. 158(2), 307-21.
Christodoulou, C., Oikonomopoulos G., Koliou G. Angeliki, Kostopoulos I., Kotoula V., Bobos M., et al. (2018).  Evaluation of the Insulin-like Growth Factor Receptor Pathway in Patients with Advanced Breast Cancer Treated with Trastuzumab.. Cancer Genomics Proteomics. 15(6), 461-471.
Koutras, A., Kalogeras K. T., Wirtz R. M., Alexopoulou Z., Bobos M., Zagouri F., et al. (2015).  Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study.. J Transl Med. 13, 171.
Koutras, A., Lazaridis G., Koliou G-A., Kouvatseas G., Christodoulou C., Pectasides D., et al. (2018).  Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study.. PLoS One. 13(12), e0207707.
Liontos, M., Trigka E-A., Korkolopoulou P., Tzannis K., Lainakis G., Koutsoukos K., et al. (2017).  Expression and prognostic significance of VEGF and mTOR pathway proteins in metastatic renal cell carcinoma patients: a prognostic immunohistochemical profile for kidney cancer patients.. World J Urol. 35(3), 411-419.
Korantzis, I., Kalogeras K. T., Papaxoinis G., Kotoula V., Koutras A., Soupos N., et al. (2012).  Expression of angiogenic markers in the peripheral blood of patients with advanced breast cancer treated with weekly docetaxel.. Anticancer Res. 32(10), 4569-80.
Kotoula, V., Krikelis D., Karavasilis V., Koletsa T., Eleftheraki A. G., Televantou D., et al. (2012).  Expression of DNA repair and replication genes in non-small cell lung cancer (NSCLC): a role for thymidylate synthetase (TYMS).. BMC Cancer. 12, 342.
Kotoula, V., Fostira F., Papadopoulou K., Apostolou P., Tsolaki E., Lazaridis G., et al. (2017).  The fate of BRCA1-related germline mutations in triple-negative breast tumors.. Am J Cancer Res. 7(1), 98-114.
Fountzilas, G., Valavanis C., Kotoula V., Eleftheraki A. G., Kalogeras K. T., Tzaida O., et al. (2012).  HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.. J Transl Med. 10, 10.
Razis, E., Kalogeras K. T., Kotoula V., Eleftheraki A. G., Nikitas N., Kronenwett R., et al. (2012).  Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression.. Clin Breast Cancer. 12(3), 183-93.
Lakis, S., Dimoudis S., Kotoula V., Alexopoulou Z., Kostopoulos I., Koletsa T., et al. (2016).  Interaction Between Beta-Catenin and EGFR Expression by Immunohistochemistry Identifies Prognostic Subgroups in Early High-risk Triple-negative Breast Cancer.. Anticancer Res. 36(5), 2365-78.
Kalofonos, H. P., Papakostas P., Makatsoris T., Papamichael D., Vourli G., Xanthakis I., et al. (2010).  Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancer.. Anticancer Res. 30(10), 4325-33.
Mountzios, G., Aravantinos G., Alexopoulou Z., Timotheadou E., Matsiakou F., Christodoulou C., et al. (2016).  Lessons from the past: Long-term safety and survival outcomes of a prematurely terminated randomized controlled trial on prophylactic vs. hemoglobin-based administration of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia.. Mol Clin Oncol. 4(2), 211-220.
Murray, S., Karavasilis V., Bobos M., Razis E., Papadopoulos S., Christodoulou C., et al. (2012).  Molecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer.. J Exp Clin Cancer Res. 31, 77.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.